A Double-Blind, Randomized, Multicenter, Active-Comparative, 12-Week Study to Assess the Efficacy and Safety of the Drug in Conjunction With Another Drug in Korean Patients With Primary Hypercholesterolemia

NCT00157911 Phase 3 COMPLETED

Patients undergo 4-week placebo lead-in and diet period, and 12-week treatment period. Clinical efficacy and safety is evaluated at weeks 4, 8 and 12. This study takes approximately 18 weeks for an individual patient to complete including post-visit at week 14.

Details

Lead sponsor	Organon and Co
Phase	Phase 3
Status	COMPLETED
Enrolment	136
Start date	2002-12
Completion	2003-12

Conditions

• Hypercholerolemia

Interventions

• MK0653; ezetimibe / Duration of Treatment: 12 weeks
• Comparator: simvastatin / Duration of Treatment: 12 weeks

Primary outcomes

• LDL-C